PARIS and MONHEIM, Germany, Jan. 10, 2025 /PRNewswire/ -- Iktos, a leader in Artificial Intelligence (AI) and Robotics for drug design, and Cube Biotech, a pioneer in membrane protein production and ...

The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

GLP-1 drugs, widely used for treating metabolic disorders, often face issues with long term tolerability, leading to side effects such as sarcopenia and bone density loss. These complications ...

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and ...

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.